Product
64Cu-DOTATATE
1 clinical trial
1 indication
Indication
Neuroendocrine TumorsClinical trial
An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)Status: Completed, Estimated PCD: 2019-03-23